<DOC>
	<DOCNO>NCT00752154</DOCNO>
	<brief_summary>Curcuma longa turmeric tropical plant native south southeast tropical Asia . Perhaps active component turmeric curcumin may make 2-5 % total spice turmeric . The study drug test study curcumin . This study call cross-over study subject receive study drug certain amount time switch placebo ( inactive substance ) certain time vice versa . The subject 's participation may last 8 month . The subject randomized ( chance ; like flip coin ) receive either study drug , curcumin , placebo 4 month . After 4 month , subject take curcumin stop take begin take placebo subject take placebo stop take begin take curcumin remain 4 month . By completion study , 40 subject take curcumin placebo 4 month . Curcumin/placebo provide capsule form subject take mouth . The dose dose increase every week total 4 gram per day . Subjects blood test , complete questionnaire , see study doctor .</brief_summary>
	<brief_title>Curcumin Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<criteria>1 . Age ≥ 18 year ; read understand English 2 . Stable dose nonsteroidal antiinflammatory agent ( NSAID ) ≥ 2 week . 3 . Oral prednisone equivalent ≤ 10 mg daily stable dose ≥ 2 week ( must keep stable throughout duration protocol ) . ESR &gt; 20 mm/hr , CRP &gt; 0.8 mg/dl 4 . May use follow DMARDs : methotrexate , sulfasalazine , hydroxychloroquine leflunomide . If use DMARDs must use ≥ 12 week stable dose ≥ 4 week . If use DMARD , DMARD combination , additional DMARDs must stop ≥ 4 week baseline visit . May also participate patient DMARD , 5 . Subjects must diagnose rheumatoid arthritis base revised American College Rheumatology criterion : Presence &gt; swell &gt; 6 tender joint count ( 28 joint count ) , either ESR &gt; 20 mm/hr CRP &gt; 0.8 mg/dl 1 . Acute medical condition deem inappropriate investigator ( acute heart failure , uncontrolled diabetes mellitus , uncontrolled hypertension ) 2 . AST/ALT &gt; 1.5 upper limit normal ( ULN ) 3 . Serum creatinine &gt; 1.6 mg/dl 4 . Hemoglobin/Hematocrit &lt; 10.0 gram/dl/ 30.0 5 . Platelet count &lt; 100,000 6 . Current use warfarin ( drug interaction curcumin warfarin ) . 7 . Currently biologic therapy ( must stop etanercept ≥ 4 week adalimumab infliximab ≥ 8 week time Time 1 visit ) , 8 . Women pregnant , 9 . Subjects take digoxin , warfarin and/or heparin , 10 . Subjects history antiphospholipid syndrome thrombophilic state , 11 . Subjects INR &gt; = 1.5 baseline , 12 . Subjects acute episode ( ) cholecystitis within last 6 month , 13 . Subjects active peptic ulcer disease within last 6 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Subjects</keyword>
	<keyword>active</keyword>
	<keyword>Rheumatoid</keyword>
	<keyword>Arthritis</keyword>
	<keyword>revise</keyword>
	<keyword>American</keyword>
	<keyword>College</keyword>
	<keyword>Rheumatology</keyword>
	<keyword>Criteria</keyword>
</DOC>